Stock Day Media

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

May 18, 2020May 18, 2020 Stock Day Media 224 Views cydy, cytodyn, Leronlimab, phase3trial, remdesivir, threearmcomparitive

VANCOUVER, Washington, May 18, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19

April 15, 2020April 15, 2020 Stock Day Media 271 Views covid19, cydy, cytodyn, Leronlimab

VANCOUVER, Washington, April 15, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s Leronlimab

April 8, 2020April 8, 2020 Stock Day Media 323 Views coronavirus, coronavirusnews, covid19trial, cydy, cytodyns, Leronlimab, novanthealth

Novant Health operates a fully integrated healthcare system throughout four states VANCOUVER, Washington and WINSTON-SALEM, N.C., April 07, 2020 (GLOBE

BioTech

Treatment with CytoDyn’s Leronlimab Indicates Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients (CYDY)

April 2, 2020April 2, 2020 Stock Day Media 390 Views covid19patients, cytodyn, Leronlimab, severelyill

VANCOUVER, Washington, April 02, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients

March 30, 2020March 30, 2020 Stock Day Media 366 Views coronavirus, covid19, covid19patients, covid19treatment, Leronlimab, newyorkmedicalcenter, stockdaypodcast

VANCOUVER, Washington, March 30, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

Leronlimab

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S.

CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19

Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7

Severely Ill COVID-19 Patient at Leading Southern California Medical Center Extubated Three Days After Treatment with CytoDyn’s Leronlimab; Two Moderate COVID-19 Patients Removed from External Oxygen Following One Day of Treatment with Leronlimab

Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s Leronlimab

Treatment with CytoDyn’s Leronlimab Indicates Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients (CYDY)

CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks

Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients

CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval

CytoDyn Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV